DENDRIMERS CONTAINING LUMINESCENT PLATINUM(II) COMPOUNDS FOR ORGANIC LIGHT-EMITTING DEVICES AND THEIR PREPARATION

Abstract

Disclosed is a class of dendrimers containing cyclometalated tridentate platinum(II) compounds with one monoanionic auxiliary ligand, both coordinated to a platinum (II) metal center and having the chemical structure shown in generic formula (I), wherein at least one of R.sub.1, R.sub.2 and R.sub.3 being a dendrimeric moiety of general formula (II), each being optionally substituted.

##STR00001##

Claims

1. A luminescent dendrimers containing cyclometalated tridentate platinum(II) compounds with one monoanionic auxiliary ligand, both coordinated to a platinum(II) metal center and having the chemical structure represented by the following general formula (I), ##STR00017## wherein (a) X, Y and Z are cyclic structures; (b) any combinations of the rings X, Y and Z can be fused together with each other or the rings X, Y and Z can be non-fused with each other; (c) R.sub.1, R.sub.2 and R.sub.3 are the same or different and independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkylaryl, cycloalkyl, OR, NR.sub.2, SR, C(O)R, C(O)OR, C(O)NR.sub.2, CN, CF.sub.3, NO.sub.2, SO.sub.2, SOR, SO.sub.3R, halo, aryl, heteroaryl, heterocyclic group or a dendrimeric moiety of general formula (II), wherein R is independently alkyl, alkenyl, alkynyl, alkyaryl, aryl or cycloalkyl, with at least one of R.sub.1, R.sub.2, and R.sub.3 being a dendrimeric moiety of general formula (II), each being optionally substituted; ##STR00018## wherein: (i) Unit A is the central part of the dendron and the branching point of the dendrimer; (ii) Unit B is the surface groups or dendron of the dendrimer, or none; (d) R.sub.4 is an optionally substituted ligand attached to the platinum(II) atom that is optionally linked or unlinked to the tridentate ligand.

2. The platinum(II) compound according to claim 1, wherein the X and Y are independently selected from, but is not limited to, pyridine, imidazole, benzimidazole, naphthoimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, pyrazole, triazole, tetrazole, pyridazine, triazine, tetrazine, triazole, indole, oxazole, isoxazole, isothiazole, benzothiazole and benzoxazole, each being optionally substituted; preferably, X and Y are benzimidazole.

3. The platinum(II) compound according to claim 1, wherein the Z is selected from, but is not limited to, benzene, naphthalene, anthracene, pyrene, fluorene, pyrene, pyridine, imidazole, benzimidazole, naphthoimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, pyrazole, triazole, tetrazole, pyridazine, triazine, tetrazine, triazole, indole, oxazole, isoxazole, isothiazole, benzothiazole, benzoxazole, thiophene, furan, benzofuran and dibenzofuran, each being optionally substituted; preferably, Z is benzene.

4. The platinum(II) compound according to claim 1, wherein A and B are optionally substituted N or C atom, benzene, phenyl derivatives, pyridine or pyridyl derivatives, thiophene, furan, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, pyrrole, pyrazine, pyridazine, pyrimidine, benzimidazole, benzofuran, benzothiazole, indole, naphthalene, triazole, tetrazole, pyran, thiapyran, oxadiazole, triazine, tetrazine, carbazole, dibenzothiophene, dibenzofuran, with one or more alkyl, alkenyl, alkynyl, alkylaryl, cycloalkyl, OR, NR.sub.2, SR, C(O)R, C(O)OR, C(O)NR.sub.2, CN, CF.sub.3, NO.sub.2, SO.sub.2, SOR, SO.sub.3R, halo, aryl, heteroaryl, heterocyclic group, wherein R is independently alkyl, alkenyl, alkynyl, alkyaryl, aryl or cycloalkyl, or other appropriate aromatic moieties, each being optionally substituted; preferably, A and B are optionally substituted N or C atom, benzene, benzimidazole, oxadiazole and carbazole, with one or more alkyl as substituents.

5. The platinum(II) compound according to claim 1, wherein the R.sub.4 comprises halogen, alkyl, cycloalkyl, alkenyl, arylalkenyl, aryl, alkynyl, arylalkynyl, heteroaryl, heterocyclic group, each being optionally substituted such as by a dendrimeric moiety of general formula (II); preferably, R.sub.4 comprises halogen, arylalkynyl, each being optionally substituted such as by a dendrimeric moiety of general formula (II); preferably, R.sub.4 is selected from the following: ##STR00019## ##STR00020##

6. The platinum(II) compound according to claim 1, wherein the compound is deposited as a thin layer on a substrate layer.

7. The platinum(II) compound according to claim 6, wherein the thin layer is deposited by vacuum deposition technique.

8. The platinum(II) compound according to claim 6, wherein the thin layer is deposited by spin-coating or inkjet printing.

9. The platinum(II) compound according to claim 1, wherein the compound has photoluminescence properties within a range of about 380 to 1050 nm.

10. The platinum(II) compound according to claim 1, wherein the compound emits light in response to the passage of an electric current or to a strong electric field.

11. A method for preparing a luminescent compound with a cyclometalated tridentate ligand and at least one monoaryl group coordinated to a platinum(II) metal group, comprising the following reaction: ##STR00021## wherein X and Y are independently selected from, but is not limited to, pyridine, imidazole, benzimidazole, naphthoimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, pyrazole, triazole, tetrazole, pyridazine, triazine, tetrazine, triazole, indole, oxazole, isoxazole, isothiazole, benzothiazole and benzoxazole, each being optionally substituted; Z is selected from, but is not limited to, benzene, naphthalene, anthracene, pyrene, fluorene, pyrene, pyridine, imidazole, benzimidazole, naphthoimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, pyrazole, triazole, tetrazole, pyridazine, triazine, tetrazine, triazole, indole, oxazole, isoxazole, isothiazole, benzothiazole, benzoxazole, thiophene, furan, benzofuran and dibenzofuran, each being optionally substituted; R.sub.1, R.sub.2 and R.sub.3 are the same or different and independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkylaryl, cycloalkyl, OR, NR.sub.2, SR, C(O)R, C(O)OR, C(O)NR.sub.2, CN, CF.sub.3, NO.sub.2, SO.sub.2, SOR, SO.sub.3R, halo, aryl, heteroaryl, heterocyclic group or a dendrimeric moiety of general formula (II), wherein R is independently alkyl, alkenyl, alkynyl, alkyaryl, aryl or cycloalkyl, and dendrimeric moieties, each being optionally substituted; R.sub.4 is an optionally substituted ligand attached to the platinum atom, in which, R.sub.4 is selected from, but is not limited to, halogen, alkyl, alkyl, cycloalkyl, alkenyl, arylalkenyl, aryl, alkynyl, arylalkynyl, heteroaryl, heterocyclic group, each being optionally substituted such as by a dendrimeric moiety of general formula (II).

12. The method according to claim 11 wherein a luminescent compound is prepared.

13. The method according to claim 11 wherein the platinum(II) metal center is a dopant included in the light-emitting layer of the light-emitting device.

14. A light-emitting device with an ordered structure comprising an anode, a hole-transporting layer, a light-emitting layer, an electron-transporting layer and a cathode, wherein the light-emitting layer comprises a platinum(II) compound having a chemical structure represented by the following general formula (I), ##STR00022## wherein X and Y are independently selected from, but is not limited to, pyridine, imidazole, benzimidazole, naphthoimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, pyrazole, triazole, tetrazole, pyridazine, triazine, tetrazine, triazole, indole, oxazole, isoxazole, isothiazole, benzothiazole and benzoxazole, each being optionally substituted; Z is selected from, but is not limited to, benzene, naphthalene, anthracene, pyrene, fluorene, pyrene, pyridine, imidazole, benzimidazole, naphthoimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, pyrazole, triazole, tetrazole, pyridazine, triazine, tetrazine, triazole, indole, oxazole, isoxazole, isothiazole, benzothiazole, benzoxazole, thiophene, furan, benzofuran and dibenzofuran, each being optionally substituted; R.sub.1, R.sub.2 and R.sub.3 are the same or different and independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkylaryl, cycloalkyl, OR, NR.sub.2, SR, C(O)R, C(O)OR, C(O)NR.sub.2, CN, CF.sub.3, NO.sub.2, SO.sub.2, SOR, SO.sub.3R, halo, aryl, heteroaryl, heterocyclic group or a dendrimeric moiety of general formula (II), wherein R is independently alkyl, alkenyl, alkynyl, alkyaryl, aryl or cycloalkyl, and dendrimeric moieties with general formula (II), each being optionally substituted, with at least one of R.sub.1, R.sub.2, and R.sub.3 being a dendrimeric moiety; R.sub.4 is an optionally substituted ligand attached to the platinum atom; R.sub.4 is selected from, but is not limited to, halogen, alkyl, cycloalkyl, alkenyl, arylalkenyl, aryl, alkynyl and arylalkynyl, heteroaryl, heterocyclic, each being optionally substituted such as by a dendrimeric moiety of general formula (II); ##STR00023## wherein: (i) Unit A is the central part of the dendron and the branching point of the dendrimer; (ii) Unit B is the surface groups or dendron of the dendrimer, or none.

15. The light-emitting device of claim 14, wherein the light-emitting layer is prepared using vacuum deposition technique.

16. The light-emitting device of claim 14, wherein the light-emitting layer is prepared using solution processing technique.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Scheme 1 is the chemical structures of compounds 1-14.

[0025] FIG. 1 is a schematic diagram of the basic structure of an OLED, in accordance with an embodiment of the invention.

[0026] FIG. 2 shows the UV-vis absorption spectra of compounds 1-4 in dichloromethane at 298 K.

[0027] FIG. 3 shows the UV-vis absorption spectra of compounds 5 and 11 in dichloromethane at 298 K.

[0028] FIG. 4 shows the UV-vis absorption spectra of compounds 12 and 13 in dichloromethane at 298 K.

[0029] FIG. 5 shows the UV-vis absorption spectra of compounds 6-9 in dichloromethane at 298 K.

[0030] FIG. 6 shows the UV-vis absorption spectra of compounds 10 and 14 in dichloromethane at 298 K.

[0031] FIG. 7 shows the normalized photoluminescence spectra of compounds 1-4 in dichloromethane at 298 K.

[0032] FIG. 8 shows the normalized photoluminescence spectra of compounds 5 and 11-13 in dichloromethane at 298 K.

[0033] FIG. 9 shows the normalized photoluminescence spectra of compounds 6-9 in dichloromethane at 298 K.

[0034] FIG. 10 shows the normalized photoluminescence spectra of compounds 10 and 14 in dichloromethane at 298 K.

[0035] FIG. 11 shows the normalized photoluminescence spectra of thin films of 20 wt % compounds 6-9 doped into 4,4,4-tris(carbazol-9-yl)triphenylamine (TCTA) 2,7-bis(diphenylphosphoryl)-9,9-spirobifluorene (SPPO13) (1:1) at 298 K.

[0036] FIG. 12 shows the normalized photoluminescence spectra of thin films of 5 wt % compounds 5 and 11-13 doped into 1,3-bis(carbazol-9-yl)benzene (MCP) at 298 K.

[0037] FIG. 13 shows the normalized EL spectra of solution-processable OLEDs made with (a) 6, (b) 7, (c) 8 and (d) 9 doped with different concentrations.

[0038] FIG. 14 shows the EQEs of solution-processable OLEDs made with (a) 6, (b) 7, (c) 8 and (d) 9 doped with different concentrations.

[0039] FIG. 15 shows the normalized EL spectra of solution-processable OLEDs doped with 15 wt % 6-9, 12 and 13.

DETAILED DESCRIPTION OF THE INVENTION

[0040] The present invention is directed to the synthesis and luminescence studies of a novel class of dendrimers containing cyclometalated tridentate platinum(II) compounds with one monoanionic auxiliary ligand, both coordinated to a platinum(II) metal center and having the chemical structure shown in generic formula (I),

##STR00004## [0041] wherein [0042] a) X, Y and Z are cyclic structures; [0043] b) any combinations of the rings X, Y and Z can be fused together with each other or the rings X, Y and Z can be non-fused with each other; [0044] c) R.sub.1, R.sub.2 and R.sub.3 are the same or different and independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkylaryl, cycloalkyl, OR, NR.sub.2, SR, C(O)R, C(O)OR, C(O)NR.sub.2, CN, CF.sub.3, NO.sub.2, SO.sub.2, SOR, SO.sub.3R, halo, aryl, heteroaryl, heterocyclic group or a dendrimeric moiety of general formula (II), wherein R is independently alkyl, alkenyl, alkynyl, alkyaryl, aryl or cycloalkyl, with at least one of R.sub.1, R.sub.2, and R.sub.3 being a dendrimeric moiety of general formula (II), each being optionally substituted;

##STR00005## [0045] wherein: [0046] (i) Unit A is the central part of the dendron and the branching point of the dendrimer; [0047] (ii) Unit B is the surface groups or dendron of the dendrimers, or none; [0048] d) R.sub.4 is an optionally substituted ligand attached to the platinum(II) atom that is optionally linked or unlinked to the tridentate ligand.

[0049] X and Y are independently selected from, but is not limited to, pyridine, imidazole, benzimidazole, naphthoimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, pyrazole, triazole, tetrazole, pyridazine, triazine, tetrazine, triazole, indole, oxazole, isoxazole, isothiazole, benzothiazole and benzoxazole, each being optionally substituted;

[0050] Z is selected from, but is not limited to, benzene, naphthalene, anthracene, pyrene, fluorene, pyrene, pyridine, imidazole, benzimidazole, naphthoimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, pyrazole, triazole, tetrazole, pyridazine, triazine, tetrazine, triazole, indole, oxazole, isoxazole, isothiazole, benzothiazole, benzoxazole, thiophene, furan, benzofuran and dibenzofuran, each being optionally substituted;

[0051] A and B are optionally substituted N or C atom, benzene, phenyl derivatives, pyridine or pyridyl derivatives, thiophene, furan, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, pyrrole, pyrazine, pyridazine, pyrimidine, benzimidazole, benzofuran, benzothiazole, indole, naphthalene, triazole, tetrazole, pyran, thiapyran, oxadiazole, triazine, tetrazine, carbazole, dibenzothiophene, dibenzofuran, with one or more alkyl, alkenyl, alkynyl, alkylaryl, cycloalkyl, OR, NR.sub.2, SR, C(O)R, C(O)OR, C(O)NR.sub.2, CN, CF.sub.3, NO.sub.2, SO.sub.2, SOR, SO.sub.3R, halo, aryl, heteroaryl, heterocyclic group, wherein R is independently alkyl, alkenyl, alkynyl, alkyaryl, aryl or cycloalkyl, or other appropriate aromatic moieties, each being optionally substituted.

[0052] R.sub.4 is selected from, but is not limited to, halogen, alkyl, cycloalkyl, alkenyl, arylalkenyl, aryl, alkynyl and arylalkynyl, heteroaryl, heterocyclic group, each being optionally substituted such as by a dendrimeric moiety of general formula (II). In one embodiment, R.sub.4 is optionally a substituted monoanionic ligand.

[0053] In the present disclosure the following terms are used.

[0054] The term optional or optionally means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, optionally substituted alkyl includes alkyl and substituted alkyl, as defined below. The term halo or halogen as used herein includes fluorine, chlorine, bromine and iodine. The term alkyl as used herein includes straight and branched chain alkyl groups, as well as cycloalkyl group with cyclic structure of alkyl groups. Preferred alkyl groups are those containing from one to eighteen carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, and the like. In addition, the alkyl group may be optionally substituted with one or more substituents selected from OR, NR.sub.2, SR, C(O)R, C(O)OR, C(O)NR.sub.2, CN, CF.sub.3, NO.sub.2, SO.sub.2, SOR, SO.sub.3R, halo and cyclic-amino. The term alkenyl as used herein includes both straight and branched chain alkene radicals. Preferred alkenyl groups are those containing two to eighteen carbon atoms. In addition, the alkenyl group may be optionally substituted with one or more substituents selected from OR, NR.sub.2, SR, C(O)R, C(O)OR, C(O)NR.sub.2, CN, CF.sub.3, NO.sub.2, SO.sub.2, SOR, SO.sub.3R, halo and cyclic-amino. The term alkynyl as used herein includes both straight and branched chain alkyne radicals. Preferred alkynyl groups are those containing two to eighteen carbon atoms. In addition, the alkynyl group may be optionally substituted with one or more substituents selected from OR, NR.sub.2, SR, C(O)R, C(O)OR, C(O)NR.sub.2, CN, CF.sub.3, NO.sub.2, SO.sub.2, SOR, SO.sub.3R, halo and cyclic-amino. The term arylalkynyl as used herein includes an alkynyl group which has an aromatic group as a substituent. In addition, the arylalkynyl group may be optionally substituted with one or more substituents selected from OR, NR.sub.2, SR, C(O)R, C(O)OR, C(O)NR.sub.2, CN, CF.sub.3, NO.sub.2, SO.sub.2, SOR, SO.sub.3R, halo and cyclic-amino. The term alkylaryl as used herein includes an alkyl group which has an aromatic group as a substituent. In addition, the alkylaryl group may be optionally substituted with one or more substituents selected from OR, NR.sub.2, SR, C(O)R, C(O)OR, C(O)NR.sub.2, CN, CF.sub.3, NO.sub.2, SO.sub.2, SOR, SO.sub.3R, halo and cyclic-amino; and R is selected from, but is not limited to, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic aryl and substituted heterocyclic aryl.

[0055] Aryl alone or in combination includes carbocyclic aromatic systems. The systems may contain one, two or three rings wherein each ring may be attached together in a pendant manner or may be fused. Preferably the rings are 5- or 6-membered rings.

[0056] Heteroaryl alone or in combination includes heterocyclic aromatic systems. The systems may contain one, two or three rings wherein each ring may be attached together in a pendant manner or may be fused. Preferably the rings are 5- or 6-membered rings.

[0057] Heterocyclic and heterocycle refer to a 3 to 7-membered ring containing at least one heteroatom. This includes aromatic rings including but not limited to pyridine, thiophene, furan, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, pyrrole, pyrazine, pyridazine, pyrimidine, benzimidazole, benzofuran, benzothiazole, indole, naphthalene, triazole, tetrazole, pyran, thiapyran, oxadiazole, triazine, tetrazine, carbazole, dibenzothiophene, dibenzofuran, fluorine, and non-aromatic rings including but not limited to piperazine, piperidine, and pyrrolidine. The groups of the present invention can be substituted or unsubstituted. Preferred substituents include but are not limited to alkyl, alkoxy, aryl.

[0058] Heteroatom refers to S, O, N, P, Se, Si, Te.

[0059] Substituted refers to any level of substitution although mono-, di- and tri-substitutions are preferred. Preferred substituents include hydrogen, halogen, aryl, alkyl and heteroaryl.

[0060] Benzene includes substituted or unsubstituted benzene.

[0061] Pyridine includes substituted or unsubstituted pyridine.

[0062] Thiophene includes substituted or unsubstituted thiophene.

[0063] Furan includes substituted or unsubstituted furan.

[0064] Pyrazole includes substituted or unsubstituted pyrazole.

[0065] Imidazole includes substituted or unsubstituted imidazole.

[0066] Oxazole includes substituted or unsubstituted oxazole.

[0067] Isoxazole includes substituted or unsubstituted isoxazole.

[0068] Thiazole includes substituted or unsubstituted thiazole.

[0069] Isothiazole includes substituted or unsubstituted isothiazole.

[0070] Pyrrole includes substituted or unsubstituted pyrrole.

[0071] Pyrazine includes substituted or unsubstituted pyrazine.

[0072] Pyridazine includes substituted or unsubstituted pyridazine.

[0073] Pyrimidine includes substituted or unsubstituted pyrimidine.

[0074] Benzimidazole includes substituted or unsubstituted benzimidazole.

[0075] Benzofuran includes substituted or unsubstituted benzofuran.

[0076] Benzothiazole includes substituted or unsubstituted benzothiazole.

[0077] Indole includes substituted or unsubstituted indole.

[0078] Naphthalene includes substituted or unsubstituted naphthalene.

[0079] Triazole includes substituted or unsubstituted triazole.

[0080] Tetrazole includes substituted or unsubstituted tetrazole.

[0081] Pyran includes substituted or unsubstituted pyran.

[0082] Thiapyran includes substituted or unsubstituted thiapyran.

[0083] Oxadiazole includes substituted or unsubstituted oxadiazole.

[0084] Triazine includes substituted or unsubstituted triazine.

[0085] Tetrazine includes substituted or unsubstituted tetrazine.

[0086] Carbazole includes substituted or unsubstituted carbazole.

[0087] Dibenzothiophene includes substituted or unsubstituted dibenzothiophene.

[0088] Dibenzofuran includes substituted or unsubstituted dibenzofuran.

[0089] Piperazine includes substituted or unsubstituted piperazine.

[0090] Piperidine includes substituted or unsubstituted piperidine.

[0091] Pyrrolidine includes substituted or unsubstituted pyrrolidine.

[0092] In some embodiments of the invention, the luminescent platinum(II) compounds are prepared in high purity. The synthetic method involves reacting a tridentate ligand-containing platinum(II) chloride with the corresponding auxiliary ligands under copper-catalyzed reaction condition. This reaction is carried out under a mild condition. Purification can be carried out by any method or combination of methods, including chromatography, extraction, crystallization, sublimation or any combination thereof.

[0093] The luminescent platinum(II) complexes can be used to form thin films by vacuum deposition, spin-coating, ink jet printing, or other known fabrication methods that can be applied in OLEDs. Referring to FIG. 1, an OLED has, in order, substrate, hole-injecting anode, hole-transporting layer, light-emitting layer, electron-transporting layer, and electron-injecting cathode.

[0094] Substrate is electrically insulated and can be either optically transparent, and comprises glass, plastic foil, or other appropriate material, or alternatively, may be opaque and comprises one or more semiconducting materials or ceramics. In one embodiment of the invention, the EL emission is viewed through substrate, or through both sides of the device, and substrate comprises a transparent glass substrate or a plastic foil. In other embodiments, the EL emission is viewed only through the top electrode, and substrate comprises an opaque semiconductor or ceramic wafers. Hole-injecting anode injects holes into the organic EL layer when anode is positively biased. Anode is composed of a conductive and optionally transmissive layer. In one embodiment of the invention, viewing the EL emission through the substrate is desirable, and hole-injecting anode is transparent. In other embodiments, the EL emission is viewed through the top electrode and the transmissive characteristics of anode are immaterial, and therefore any appropriate materials including metals or metal compounds having a work function of greater than 4.1 eV are used. Appropriate metals include gold, iridium, molybdenum, palladium, and platinum. In some embodiments, anode is transmissive, and suitable materials are metal oxides, including indium-tin oxide, aluminum- or indium-doped zinc oxide, tin oxide, magnesium-indium oxide, nickel-tungsten oxide, and cadmium-tin oxide. The preferred metals and metal oxides can be deposited by evaporation, sputtering, laser ablation, and chemical vapor deposition. Suitable materials for hole-transporting layer include polycyclic aromatic compounds, for example, 4,4-bis[N-(1-naphthyl)-N-phenylamino]biphenyl (NPB), 4,4-bis[N-(3-methylphenyl)-N-phenylamino]biphenyl (TPD), 4,4,4-tris[(3-methylphenyl)phenyl amino] triphenylamine (MTDATA), and di[4-(N,N-ditolyl-amino)phenyl]cyclohexane (TAPC). In addition, polymeric hole-transporting materials can be used including poly(N-vinylcarbazole) (PVK), polythiophene, polypyrrole, polyaniline, and copolymers including poly(3,4-ethylenedioxythiophene):poly(-styrene-surlfonate) (PEDOT:PSS).

[0095] Light-emitting layer in FIG. 1 is formed by doping the phosphorescent platinum(II) compound as a dopant into a host compound. Suitable host materials should be selected so that the triplet exciton can be transferred efficiently from the host material to the phosphorescent dopant material. Suitable host materials include certain aryl amines, triazoles and carbazole compounds. Examples of desirable hosts are 4,4-bis(carbazol-9-yl)biphenyl (CBP), MCP, TCTA, SPPO13, 3-(4-biphenylyl)-4-phenyl-5-tert-butylphenyl-1,2,butylphenyl-1,2,4-triazole (TAZ), p-bis(triphenylsilyl)benzene (UGH2), and PVK.

[0096] Electron-transporting layer consists of materials or mixtures of materials having a high ionization potential and wide optical band gap. Suitable electron-transporting materials include 1,3,5-tris(phenyl-2-benzimidazolyl)-benzene (TPBI), bathocuproine (BCP), bathophenanthroline (BPhen) and bis(2-methyl-8-quinolinolate)-4-(phenylphenolate)aluminum (BAlq), tris[2,4,6-trimethyl-3-(pyridin-3-yl)phenyl]borane (3TPyMB), 1,3,5-tri[(3-pyridyl)-phen-3-yl]benzene (TmPyPB), and 1,3-bis[3,5-di(pyridin-3-yl)-phenyl]benzene (BmPyPhB). In one embodiment of the invention, electron-transporting layer is prepared as an organic film by thermal evaporation, spin-coating, ink jet printing from a solution, or other known fabrication methods. Electron-injecting cathode acts as a transmissive electron injector that injects electrons into the organic EL layer of anode when cathode is negatively biased. Cathode comprises a thin fluoride layer (which may be omitted) and a metal or metal alloy, preferably having a work function of less than 4 eV. Suitable materials include Mg:Ag, Ca, Li:Al, Al.

[0097] In some embodiments of the invention, novel luminescent platinum(II) complexes are either the primary luminescent material or a secondary luminescent material in device. In some embodiment, the platinum(II) compound is employed as electrophosphorescent dopants in the multilayer solution-processable OLED with an EQE of 16.0%. Advantageously, the platinum(II) compounds can be deposited in the OLEDs by vacuum deposition, spin-coating, screen printing or ink jet printing. The excellent solubilities of these luminescent platinum(II) complexes in a variety of organic solvents permits simple and economic manufacturing and patterning of large-area displays.

[0098] In general, emissive layer is sandwiched between hole-transporting layer and electron-transporting layer. To ensure an efficient exothermic energy transfer between the host material and the dopant material, the triplet energy of the host material must be larger than that of the dopant material. In addition, both the ionization potential and the electron affinity of the host material should be larger than those of the dopant material in order to achieve efficient Frster energy transfer from the host to the dopant. In order to confine triplet excitons within emissive layer, the triplet energy of hole-transporting material and electron-transporting material should be larger than that of the dopant material.

[0099] The present invention will be illustrated more specifically by the following non-limiting examples, it being understood that changes and variations can be made therein without deviating from the scope and the spirit of the invention as hereinafter claimed. It is also understood that various theories as to why the invention works are not intended to be limiting.

Example 1

[0100] Synthesis and Characterization of Dendritic Tridentate Ligands L1-L7

[0101] Dendritic tridentate ligands, (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb, {(Cbz.sup.tBu.sub.2).sub.2-Cbz-Ph}.sub.2bzimb, Cbz.sup.tBu.sub.2-(Ph.sub.2bzimb) and (Cbz.sup.tBu.sub.2).sub.2-Cbz-(Ph.sub.2bzimb), were synthesized according to the modification of a procedure reported in the literature [Wing, K.-T.; Lin, Y.-H.; Wu, H.-H; Fungo, F. Org. Lett. 9, 4531 (2007)]. For example, to a well-degassed solution of 1,3-bis(N-(4-bromophenyl)-benzimidazol-2-yl)benzene (1.08 g, 1.75 mmol), 3,6-di-tert-butylcarbazole (0.97 g, 3.66 mmol), sodium tert-butoxide (350 mg, 3.66 mmol) and tris(dibenzylideneacetone)dipalladium(0) (80 mg, 0.09 mmol) in toluene (10 mL) was added tri-tert-butylphosphine (18 mg, 0.09 mmol). The resulting mixture was stirred and heated to reflux at 120 C. for 24 h. To the mixture was then added deionized water (20 mL). The organic phase was separated and was washed with brine solution for three times, and then extracted three times with dichloromethane. The organic extract was dried over anhydrous Na.sub.2SO.sub.4 and filtered. Further purification was done by column chromatography (70-230 mesh) using hexane-ethyl acetate (6:1, v/v) as eluent. Subsequent recrystallization by diffusion of diethyl ether vapor into a concentrated solution of the product gave (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb as a white solid (950 mg).

##STR00006## ##STR00007##

Example 2

[0102] Synthesis and Characterization of Platinum(II) Dendrimers 1-14

[0103] [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}Cl] (compound 1), [Pt({(Cbz.sup.tBu.sub.2).sub.2-Cbz-Ph}.sub.2bzimb)Cl] (compound 2), [Pt{Cbz.sup.tBu.sub.2-(Ph.sub.2bzimb)}Cl] (compound 3) and [Pt{(Cbz.sup.tBu.sub.2).sub.2-Cbz-(Ph.sub.2bzimb)}Cl] (compound 4) were synthesized according to the following methodology. Chloroplatinum(II) compounds 1-4 were synthesized from their respective cyclometalating ligands by the reaction with potassium tetrachloroplatinate(II) in acetic acid and water mixture. For example, to a well-degassed reaction mixture of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb (500 mg, 0.49 mmol) in acetic acid (30 mL) was added a solution of potassium tetrachloroplatinate(II) (225 mg, 0.54 mmol) in deionized water (5 mL). The resulting mixture was stirred and heated to reflux at 150 C. for 48 h. After filtration, the yellow precipitate was washed with water, methanol and diethyl ether. Subsequent recrystallization by diffusing diethyl ether into a concentrated dichloromethane solution of the product gave compound 1 as a yellow solid (308 mg).

[0104] Compounds 5-14 were synthesized according to the following methodology. The target compounds were synthesized by the reaction of the respective chloroplatinum(II) compounds with different alkynes in the presence of base and organic solvent. For example, compound 5 was synthesized in a mixture of L1 (100 mg, 0.33 mol) and sodium hydroxide (15 mg, 0.37 mmol) was allowed to stir in degassed methanol solution (5 mL) for 30 minutes. Then a solution of compound 1 (410 mg, 0.33 mmol) in degassed dichloromethane (20 mL) was added and the resultant solution was refluxed for 12 h. After filtration, the yellow precipitate was washed with water (10 mL), methanol (10 mL) and diethyl ether (10 mL). Subsequent recrystallization by diffusing diethyl ether into a concentrated dichloromethane solution (30 mL) of the product gave compound 5 (377 mg) as a yellow solid.

##STR00008## ##STR00009## ##STR00010## ##STR00011##

[0105] .sup.1H NMR spectra were recorded on a Bruker AVANCE 400 (400 MHz) Fourier-transform NMR spectrometer with chemical shifts reported relative to tetramethylsilane. Positive FAB mass spectra were recorded on a Thermo Scientific DFS High Resolution Magnetic Sector Mass Spectrometer. High-resolution ESI mass spectra were recorded on a Bruker maXis II High Resolution LC-QTOF Mass Spectrometer. IR spectra were recorded as KBr disk on a Bio-Rad FTS-7 FTIR spectrometer (4000-400 cm.sup.1). Elemental analyses for the metal complexes were performed on the Carlo Erba 1106 elemental analyzer at the Institute of Chemistry, Chinese Academy of Sciences in Beijing. The satisfactory results of the characteristic analyses show the high purity of all compounds 1-14. The characteristic spectral properties of compounds 1-14 are as follows.

[0106] Compound 1 [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}Cl]. Yield: 308 mg, 45%. .sup.1H NMR (400 MHz, CDCl.sub.3, 298 K, relative to Me.sub.4Si): 1.49 (s, 36H, tert-butyl protons), 6.61 (d, J=8.0 Hz, 2H, phenyl protons), 6.85 (t, J=8.0 Hz, 1H, phenyl proton), 7.29 (d, J=7.8 Hz, 2H, benzimidazolyl protons), 7.41 (t, J=7.8 Hz, 2H, benzimidazolyl protons), 7.52-7.55 (m, 10H, benzimidazolyl and carbazolyl protons), 7.81 (d, J=8.5 Hz, 4H, phenyl protons), 7.94 (d, J=8.5 Hz, 4H, phenyl protons), 8.19 (d, J=1.0 Hz, 4H, carbazolyl protons), 9.22 (d, J=7.8 Hz, 2H, benzimidazolyl protons). Positive FAB-MS: m/z 1210 [M-Cl].sup.+. Elemental analyses: Found (%): C, 69.25; H, 5.72; N, 6.48. Calcd for C.sub.72H.sub.67N.sub.6PtCl: C, 69.36; H, 5.42; N, 6.74.

[0107] Compound 2 [Pt({(Cbz.sup.tBu.sub.2).sub.2-Cbz-Ph}.sub.2bzimb)Cl]. Yield: 220 mg, 80%. .sup.1H NMR (400 MHz, CDCl.sub.3, 298 K, relative to Me.sub.4Si): 1.46 (s, 72H, tert-butyl protons), 6.78 (d, J=8.0 Hz, 2H, phenyl protons), 6.96 (t, J=8.0 Hz, 1H, phenyl proton), 7.31 (d, J=7.8 Hz, 2H, benzimidazolyl protons), 7.34 (d, J=8.6 Hz, 8H, carbazolyl protons), 7.44-7.46 (m, 10H, benzimidazolyl and carbazolyl protons), 7.58 (t, J=7.8 Hz, 2H, benzimidazolyl protons), 7.70 (dd, J=8.6 and 1.0 Hz, 4H, carbazolyl protons), 7.84 (d, J=8.6 Hz, 4H, carbazolyl protons), 7.99 (d, J=8.6 Hz, 4H, phenyl protons), 8.11-8.15 (m, 12H, carbazolyl and phenyl protons), 8.29 (d, J=1.0 Hz, 4H, carbazolyl protons), 9.28 (d, J=7.8 Hz, 2H, benzimidazolyl protons). Positive FAB-MS: m/z 2095 [M-Cl].sup.+. Elemental analyses: Found (%): C, 74.54; H, 6.30; N, 6.24. Calcd for C.sub.136H.sub.127N.sub.10PtCl.3H.sub.2O: C, 74.72; H, 6.13; N, 6.41.

[0108] Compound 3 [Pt{Cbz.sup.tBu.sub.2-(Ph.sub.2bzimb)}Cl]. Yield: 220 mg, 80%. .sup.1H NMR (400 MHz, CD.sub.2Cl.sub.2, 298 K, relative to Me.sub.4Si): 1.47 (s, 18H, tert-butyl protons), 6.65 (s, 2H, phenyl protons), 7.02 (d, J=8.6 Hz, 2H, carbazolyl protons), 7.21 (d, J=8.2 Hz, 2H, benzimidazolyl protons), 7.39-7.47 (m, 6H, benzimidazolyl and carbazolyl protons), 7.54 (t, J=8.2 Hz, 2H, benzimidazolyl protons), 7.57-7.64 (m, 8H, benzimidazolyl and phenyl protons), 8.05 (d, J=1.8 Hz, 2H, carbazolyl protons), 9.10 (d, J=8.2 Hz, 2H, benzimidazolyl protons). Positive FAB-MS: m/z 933 [M-Cl].sup.+. Elemental analyses: Found (%): C, 63.85; H, 4.44; N, 7.12. Calcd for C.sub.52H.sub.44N.sub.5PtCl.5H.sub.2O: C, 63.83; H, 4.64; N, 7.16.

[0109] Compound 4 [Pt{(Cbz.sup.tBu.sub.2).sub.2-Cbz-(Ph.sub.2bzimb)}Cl]. Yield: 220 mg, 80%. .sup.1H NMR (400 MHz, CDCl.sub.3, 298 K, relative to Me.sub.4Si): 1.48 (s, 36H, tert-butyl protons), 6.78 (s, 2H, phenyl protons), 7.17 (d, J=8.2 Hz, 2H, benzimidazolyl protons), 7.30 (d, J=8.6 Hz, 4H, carbazolyl protons), 7.35 (d, J=8.6 Hz, 2H, carbazolyl protons), 7.38 (t, J=8.2 Hz, 2H, benzimidazolyl protons), 7.49 (dd, J=8.6 and 1.8 Hz, 4H, carbazolyl protons), 7.54-7.57 (m, 6H, benzimidazolyl, carbazolyl and phenyl protons), 7.76-7.78 (m, 8H, phenyl protons), 8.15 (d, J=1.8 Hz, 2H, carbazolyl protons), 8.18 (d, J=1.8 Hz, 4H, carbazolyl protons), 9.21 (d, J=8.2 Hz, 2H, benzimidazolyl protons). Positive FAB-MS: m/z 1376 [M-Cl].sup.+. Elemental analyses: Found (%): C, 70.58; H, 5.20; N, 6.81. Calcd for C.sub.84H.sub.74N.sub.7PtCl.H.sub.2O: C, 70.55; H, 5.36; N, 6.86.

[0110] Compound 5 [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}(Ligand 1)]. Yield: 377 mg, 72%. .sup.1H NMR (400 MHz, CDCl.sub.3, 298 K, relative to Me.sub.4Si, 1.49 (s, 54H, tert-butyl protons), 6.72 (d, J=7.8 Hz, 2H, benzimidazolyl protons), 6.86 (t, J=7.8 Hz, 1H, benzimidazolyl proton), 7.31 (d, J=8.0 Hz, 2H, benzimidazolyl protons), 7.42 (t, J=8.0 Hz, 2H, benzimidazolyl protons), 7.35 (d, J=8.7 Hz, 4H, carbazolyl protons), 7.48 (dd, J=8.7 and 1.9 Hz, 4H, carbazolyl protons), 7.72 (dd, J=8.7 and 1.9 Hz, 2H, carbazolyl protons), 7.78-7.81 (m, 8H, carbazolyl and phenyl protons), 7.91-7.96 (m, 8H, phenyl protons), 8.17 (d, J=1.1 Hz, 4H, carbazolyl protons), 8.19 (s, 2H, carbazolyl protons), 9.28 (d, J=8.0 Hz, 2H, benzimidazolyl protons). Positive FAB-MS: m/z 1589 [M].sup.+. IR (KBr disk): 2089 cm.sup.1 (CC). Elemental analyses: Found (%): C, 74.62; H, 6.33; N, 6.10. Calcd for C.sub.100H.sub.95N.sub.7Pt.H.sub.2O: C, 74.69; H, 6.08; N, 6.10.

[0111] Compound 6 [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}(Ligand 2)]. Yield: 196 mg, 75%. .sup.1H NMR (400 MHz, CDCl.sub.3, 298 K, relative to Me.sub.4Si): 1.49 (s, 36H, tert-butyl protons), 6.73 (d, J=8.0 Hz, 2H, phenyl protons of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb), 6.87 (t, J=8.0 Hz, 1H, phenyl proton of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb, 7.31-7.39 (m, 6H, phenyl and benzimidazolyl protons of CCC.sub.6H.sub.4-Cbz-(PBI-4).sub.2), 7.41-7.45 (m, 6H, carbazolyl and benzimidazolyl protons of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb), 7.52-7.58 (m, 18H, phenyl and benzimidazolyl protons of CCC.sub.6H.sub.4-Cbz-(PBI-4).sub.2, carbazolyl protons of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb), 7.60-7.63 (m, 4H, carbazolyl protons of CCC.sub.6H.sub.4-Cbz-(PBI-4).sub.2 and benzimidazolyl protons of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb), 7.72 (s, 8H, phenyl protons of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb), 7.74 (dd, J=8.3 and 1.6 Hz, 2H, carbazolyl protons of CCC.sub.6H.sub.4-Cbz-(-PBI-4).sub.2), 7.85 (d, J=8.6 Hz, 4H, phenyl protons of CCC.sub.6H.sub.4-Cbz-(PBI-4).sub.2, 7.92-7.99 (m, 8H, phenyl and benzimidazolyl protons of CCC.sub.6H.sub.4-Cbz-(PBI-4).sub.2, benzimidazolyl protons of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb), 8.19 (d, J=1.6 Hz, 4H, carbazolyl protons of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb), 8.44 (d, J=1.6 Hz, 2H, carbazolyl protons of CCC.sub.6H.sub.4-Cbz-(PBI-4).sub.2), 9.28 (d, J=8.0 Hz, 2H, benzimidazolyl protons of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb). HRMS (positive ESI) found 2014.8128 [M+H].sup.+; calcd for C.sub.130H.sub.104N.sub.11Pt (m/z):2014.8147. IR(KBr disk): 2085 cm.sup.1(CC). Elemental analyses: Found (%): C, 70.53; H, 4.84; N, 6.94. Calcd for C.sub.130H.sub.103N.sub.11Pt.2CHCl.sub.3: C, 70.37; H, 4.70; N, 6.84.

[0112] Compound 7 [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}(Ligand 3)]. Yield: 208 mg, 83%. .sup.1H NMR (400 MHz, CD.sub.2Cl.sub.2, 298 K, relative to Me.sub.4Si): 1.50 (s, 36H, tert-butyl protons), 6.85 (d, J=8.0 Hz, 2H, phenyl protons of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb), 6.96 (t, J=8.0 Hz, 1H, phenyl proton of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb), 7.31-7.39 (m, 6H, phenyl and benzimidazolyl protons of CCC.sub.6H.sub.4-Cbz-(PBI-3).sub.2), 7.41-7.45 (m, 6H, carbazolyl and benzimidazolyl protons), 7.52-7.58 (m, 18H, phenyl, carbazolyl and benzimidazolyl), 7.60-7.63 (m, 4H, carbazolyl protons and benzimidazolyl protons), 7.72 (s, 8H, phenyl protons), 7.74 (dd, J=8.3 and 1.6 Hz, 2H, carbazolyl protons), 7.85 (d, J=8.6 Hz, 4H, phenyl protons), 7.92-7.99 (m, 8H, phenyl and benzimidazolyl protons), 8.19 (d, J=1.6 Hz, 4H, carbazolyl protons), 8.44 (d, J=1.6 Hz, 2H, carbazolyl protons), 9.28 (d, J=8.0 Hz, 2H, benzimidazolyl protons). HRMS (positive ESI) found 2014.8018 [M+H].sup.+; calcd for C.sub.130H.sub.104N.sub.11Pt (m/z): 2014.8147. IR(KBr disk): 2085 cm.sup.1(CC). Elemental analyses: Found (%): C, 74.94; H, 5.26; N, 7.36. Calcd for C.sub.130H.sub.103N.sub.11Pt.CH.sub.2Cl.sub.2: C, 74.95; H, 5.04; N, 7.34.

[0113] Compound 8 [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}(Ligand 4)]. Yield: 202 mg, 80%. .sup.1H NMR (400 MHz, CDCl.sub.3, 298 K, relative to Me.sub.4Si): 1.39 (s, 18H, tert-butyl protons), 1.49 (s, 36H, tert-butyl protons), 6.73 (d, J=8.0 Hz, 2H, phenyl protons), 6.88 (t, J=8.0 Hz, 1H, phenyl proton), 7.33 (d, J=7.9 Hz, 2H, benzimidazolyl protons), 7.45 (t, J=7.9 Hz, 2H, benzimidazolyl protons of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb), 7.56-7.66 (m, 16H, benzimidazolyl, carbazolyl and phenyl protons), 7.70 (d, J=8.5 Hz, 2H, carbazolyl protons), 7.82-7.87 (m, 6H, carbazolyl and phenyl protons), 7.95-7.98 (m, 8H, phenyl proton) 8.02 (d, J=8.2 Hz, 2H, phenyl protons), 8.12 (d, J=8.4 Hz, 4H, phenyl protons), 8.20 (d, J=1.7 Hz, 4H, carbazolyl protons), 8.28 (d, J=8.4 Hz, 4H, phenyl protons), 8.56 (d, J=1.7 Hz, 2H, carbazolyl protons), 9.29 (d, J=7.9 Hz, 2H, benzimidazolyl protons of (Cbz.sup.tBu.sub.2-Ph).sub.2bzimb). HRMS (positive ESI) found 2030.8533 [M+H].sup.+; calcd for C.sub.128H.sub.112N.sub.11O.sub.2Pt (m/z):2030.8671. IR(KBr disk): 2085 cm.sup.1 (CC). Elemental analyses: Found (%): C, 71.82; H, 5.31; N, 7.25. Calcd for C.sub.128H.sub.111N.sub.11O.sub.2Pt.CHCl.sub.3: C, 72.07; H, 5.25; N, 7.17.

[0114] Compound 9 [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}(Ligand 5)]. Yield: 212 mg, 84%. .sup.1H NMR (400 MHz, CD.sub.2Cl.sub.2, 298 K, relative to Me.sub.4Si): 1.39 (s, 18H, tert-butyl protons), 1.50 (s, 36H, tert-butyl protons), 6.86 (d, J=7.5 Hz, 2H, phenyl protons), 6.88 (t, J=7.5 Hz, 1H, phenyl proton), 7.41 (d, J=8.0 Hz, 2H, benzimidazolyl protons), 7.50 (t, J=8.0 Hz, 2H, benzimidazolyl protons), 7.57-7.63 (m, 12H, carbazolyl and phenyl protons), 7.66 (t, J=8.0 Hz, 2H, benzimidazolyl protons), 7.71-7.76 (m, 6H, carbazolyl and phenyl protons of), 7.91 (m, 6H, carbazolyl and phenyl protons), 7.99-8.05 (m, 8H, phenyl protons), 8.12-8.17 (m, 6H, phenyl protons), 8.23 (d, J=1.8 Hz, 4H, carbazolyl protons), 8.61 (d, J=1.8 Hz, 2H, phenyl protons), 8.67 (d, J=1.8 Hz, 2H, carbazolyl protons), 9.24 (d, J=8.0 Hz, 2H, benzimidazolyl protons). HRMS (positive ESI) found 2030.8534 [M+H].sup.+; calcd for C.sub.128H.sub.112N.sub.11O.sub.2Pt (m/z): 2030.8671. IR(KBr disk): 2085 cm.sup.1 (CC). Elemental analyses: Found (%): C, 73.81; H, 5.40; N, 7.33. Calcd for C.sub.128H.sub.111N.sub.11O.sub.2Pt.5CHCl.sub.3: C, 73.84; H, 5.38; N, 7.37.

[0115] Compound 10 [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}(Ligand 6)]. Yield: 210 mg, 83%. .sup.1H NMR (400 MHz, CDCl.sub.3, 298 K, relative to Me.sub.4Si): 1.39 (s, 18H, tert-butyl protons), 1.49 (s, 36H, tert-butyl protons), 6.71 (d, J=7.7 Hz, 2H, phenyl protons), 6.71 (d, J=7.7 Hz, 1H, phenyl proton), 7.25 (d, J=8.6 Hz, 2H, phenyl protons), 7.30 (d, J=8.0 Hz, 2H, benzimidazolyl protons), 7.35 (d, J=8.6 Hz, 4H, phenyl protons), 7.41 (t, J=8.0 Hz, 2H, benzimidazolyl protons), 7.55-7.58 (m, 14H, benzimidazolyl carbazolyl protons and phenyl protons), 7.64 (d, J=8.6 Hz, 4H, phenyl protons), 7.73 (d, J=8.6 Hz, 2H, phenyl protons), 7.80 (d, J=8.6 Hz, 4H, phenyl protons of), 7.84 (d, J=8.6 Hz, 4H, phenyl protons), 7.95 (d, J=8.6 Hz, 4H, phenyl protons), 8.10 (d, J=8.6 Hz, 4H, phenyl protons), 8.19 (d, J=1.8 Hz, 4H, carbazolyl protons), 8.22 (d, J=8.6 Hz, 4H, phenyl protons), 9.27 (d, J=8.0 Hz, 2H, benzimidazolyl protons). Positive FAB-MS: m/z 2031 [M].sup.+. IR(KBr disk): 2083 cm.sup.1(CC). Elemental analyses: Found (%): C, 74.20; H, 5.53; N, 7.47. Calcd for C.sub.128H.sub.113N.sub.11O.sub.2Pt.5CH.sub.2Cl.sub.2: C, 74.38; H, 5.54; N, 7.43.

[0116] Compound 11 [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}(Ligand 7)]. Yield: 500 mg, 52%. .sup.1H NMR (400 MHz, CDCl.sub.3, 298 K, relative to Me.sub.4Si): 1.46 (s, 72H, tert-butyl protons), 1.48 (s, 36H, tert-butyl protons), 6.90 (d, J=7.7 Hz, 2H, phenyl protons), 6.98 (t, J=7.7 Hz, 1H, phenyl proton), 7.35 (d, J=8.6 Hz, 8H, carbazolyl protons), 7.38 (d, J=8.6 Hz, 4H, carbazolyl protons), 7.45-7.49 (m, 14H, benzimidazolyl and carbazolyl protons), 7.64-7.69 (m, 4H, benzimidazolyl and carbazolyl protons), 7.71 (dd, J=8.6 and 1.4 Hz, 4H, carbazolyl protons), 7.77 (d, J=8.1 Hz, 2H, phenyl protons), 7.80 (d, J=8.6 Hz, 2H, carbazolyl protons), 7.85 (d, J=8.6 Hz, 4H, carbazolyl protons), 8.03 (d, J=8.1 Hz, 4H, phenyl protons), 8.07 (d, J=8.1 Hz, 2H, phenyl protons), 8.13-8.19 (m, 18H, benzimidazolyl, carbazolyl and phenyl protons), 8.27 (d, J=1.4 Hz, 2H, carbazolyl protons), 8.29 (d, J=1.4 Hz, 4H, carbazolyl protons), 9.34 (d, J=7.7 Hz, 2H, benzimidazolyl protons). Positive FAB-MS: m/z 2915 [M].sup.+. IR (KBr disk): 2083 cm.sup.1 (CC). Elemental analyses: Found (%): C, 77.10; H, 6.41; N, 5.91. Calcd for C.sub.196H.sub.185N.sub.13Pt.CH.sub.2Cl.sub.2: C, 77.02; H, 6.17; N, 5.90.

[0117] Compound 12 [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}(Ligand 7)]. Yield: 370 mg, 64%. .sup.1H NMR (400 MHz, CDCl.sub.3, 298 K, relative to Me.sub.4Si): 1.47 (s, 18H, tert-butyl protons), 1.48 (s, 36H, tert-butyl protons), 6.68 (s, 2H, phenyl protons), 7.01 (d, J=8.6 Hz, 2H, phenyl protons), 7.19 (d, J=8.3 Hz, 2H, benzimidazolyl protons), 7.37-7.43 (m, 10H, benzimidazolyl, carbazolyl and phenyl protons), 7.48 (dd, J=8.7 and 1.4 Hz, 4H, carbazolyl protons), 7.54-7.62 (m, 10H, benzimidazolyl, carbazolyl and phenyl protons), 7.66 (dd, J=8.7 and 1.4 Hz, 2H, carbazolyl protons), 7.75 (d, J=8.5 Hz, 2H, phenyl protons), 7.79 (d, J=8.7 Hz, 2H, carbazolyl protons), 8.03 (d, J=1.4 Hz, 2H, carbazolyl protons), 8.05 (d, J=8.5 Hz, 2H, phenyl protons), 8.17 (d, J=1.4 Hz, 4H, carbazolyl protons), 8.26 (d, J=1.4 Hz, 2H, carbazolyl protons), 9.26 (d, J=8.3 Hz, 2H, benzimidazolyl protons). Positive FAB-MS: m/z 1754 [M].sup.+. IR (KBr disk): 2089 cm.sup.1(CC). Elemental analyses: Found (%): C, 74.56; H, 5.65; N, 6.30. Calcd for C.sub.112H.sub.102N.sub.8Pt.5CHCl.sub.3: C, 74.45; H, 5.69; N, 6.17.

[0118] Compound 13 [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}(Ligand 7)]. Yield: 406 mg, 56%. .sup.1H NMR (400 MHz, CDCl.sub.3, 298 K, relative to Me.sub.4Si): 1.48 (s, 36H, tert-butyl protons), 1.49 (s, 36H, tert-butyl protons), 6.88 (s, 2H, phenyl protons), 7.23 (d, J=8.3 Hz, 2H, benzimidazolyl protons), 7.32 (d, J=8.6 Hz, 4H, carbazolyl protons), 7.37-7.40 (m, 6H, carbazolyl protons), 7.43 (t, J=8.3 Hz, 2H, benzimidazolyl protons), 7.47-7.51 (m, 8H, carbazolyl protons), 7.55-7.58 (m, 4H, carbazolyl and phenyl protons), 7.62-7.72 (m, 12H, benzimidazolyl, carbazolyl and phenyl protons), 7.77 (d, J=8.5 Hz, 2H, phenyl protons), 7.80 (d, J=8.1 Hz, 2H, carbazolyl protons), 8.07 (d, J=8.5 Hz, 2H, phenyl protons), 8.16-8.19 (m, 10H, carbazolyl protons), 8.27 (d, J=1.4 Hz, 2H, carbazolyl protons), 9.30 (d, J=8.3 Hz, 2H, benzimidazolyl protons). Positive FAB-MS: m/z 2196 [M].sup.+. IR (KBr disk): 2083 cm.sup.1(CC). Elemental analyses: Found (%): C, 77.40; H, 6.18; N, 6.08. Calcd for C.sub.144H.sub.132N.sub.10Pt.2H.sub.2O: C, 77.43; H, 6.14; N, 6.27.

[0119] Compound 14 [Pt{(Cbz.sup.tBu.sub.2-Ph).sub.2bzimb}(Ligand 6)]. Yield: 205 mg, 78%. .sup.1H NMR (400 MHz, CDCl.sub.3, 298 K, relative to Me.sub.4Si): 1.39 (s, 18H, tert-butyl protons), 1.48 (s, 36H, tert-butyl protons), 6.86 (d, J=7.5 Hz, 2H, phenyl protons), 7.20 (d, J=8.0 Hz, 2H, benzimidazolyl protons), 7.25 (d, J=8.5 Hz, 2H, phenyl protons), 7.31 (d, J=8.6 Hz, 4H, carbazolyl protons), 7.34-7.41 (m, 10H, benzimidazolyl and phenyl protons) 7.49 (dd, J=8.6 and 1.8 Hz, 4H, carbazolyl protons), 7.54-7.60 (m, 10H, benzimidazolyl, carbazolyl and phenyl protons), 7.63-7.69 (m, 10H, carbazolyl and phenyl protons), 7.74 (d, J=8.5 Hz, 2H, phenyl protons), 7.80 (d, J=8.5 Hz, 4H, phenyl protons), 8.15 (d, J=1.8 Hz, 2H, carbazolyl protons), 8.18 (d, J=1.8 Hz, 4H, carbazolyl protons), 8.22 (d, J=8.5 Hz, 4H, phenyl protons), 9.28 (d, J=8.0 Hz, 2H, benzimidazolyl protons). Positive FAB-MS: m/z 2194 [M].sup.+. IR (KBr disk): 2083 cm.sup.1(CC). Elemental analyses: Found (%): C, 75.56; H, 5.48; N, 7.52. Calcd for C.sub.140H.sub.120N.sub.12O.sub.2Pt.1.5H.sub.2O: C, 75.59; H, 5.57; N, 7.56.

##STR00012## ##STR00013## ##STR00014## ##STR00015## ##STR00016##

Example 3

[0120] UV-Vis Absorption Properties

[0121] The UV-vis absorption spectra of compounds 1-14 in dichloromethane solution at 298 K show intense vibronic-structured absorption bands at 283-330 nm and moderately intensevibronic-structured absorption bands at 345-480 nm. The UV-vis absorption data are summarized in Table 1.

[0122] FIG. 2 depicts the UV-vis absorption spectra for compounds 1-4. The higher-energy absorptions for compounds 1-4 are assigned to spin-allowed intraligand (IL) .fwdarw.* transitions of the cyclometalated bzimb ligands and carbazole units. The lower-energy absorptions are attributed to IL -* transitions of the cyclometalated bzimb ligands, with substantial mixing of metal-to-ligand charge transfer (MLCT) [d(Pt).fwdarw.*(bzimb)]. The higher-energy absorption bands for compounds 5, 11-13 at 280-330 nm are assigned to spin-allowed IL -* transitions of the cyclometalated bzimb ligands and carbazole units, with the molar extinction coefficients increasing with the number of carbazole units in the complexes. This trend can be seen in the comparison between compounds 5 and 11 as shown in FIG. 3 and compounds 12 and 13 as shown in FIG. 4. The lower-energy absorption bands are attributed to IL .fwdarw.* transitions of the cyclometalated bzimb ligands, with substantial mixing of MLCT [d(Pt).fwdarw.*(bzimb)] and ligand-to-ligand charge transfer (LLCT) [(CCR).fwdarw.*(bzimb)] characters, as supported by the insensitivity towards the choice of the alkynes. However, it is found that this lower-energy absorption band is sensitive to the substitution on the 5-position of the bzimb ligands. A significant red-shift is observed for compounds 12 and 13 which contain carbazole dendrimers at the 5-position of the bzimb ligand compared with the other complexes without substituents as shown in FIG. 4. Such red shifts could be rationalized by the direct incorporation of the carbazole dendrimers at the 5-position of the bzimb ligand, which is connected through the electron-donating nitrogen atom. This would lead to the destabilization of the HOMO energy level relative to the lowest unoccupied molecular orbital (LUMO) energy level for compounds 12 and 13, thus narrowing the HOMO-LUMO energy gap, leading to a red shift in the transition energy.

[0123] FIGS. 5 and 6 depict the UV-vis absorption spectra for compounds 6-10 and 14. Compounds 6-10 and 14 show intense vibronic-structured absorption bands at 290-340 nm with a moderately intense vibronic-structured band at 365-410 nm. The absorption bands at 300 nm are attributed to the spin-allowed IL .fwdarw.* transitions of the carbazole or triphenylamine and bzimbunits, whereas the lower-energy absorption bands at ca. 305-390 nm could be assigned as the .fwdarw.* transitions from the electron-donating carbazole or triphenylamine moiety to the electron-accepting phenylbenzimidazole or oxadiazole moiety, mixing with the IL .fwdarw.* transitions of the cyclometalated bzimb ligand. By weakening the -conjugation between the donor and acceptor moieties via meta-substitution instead of the para-substitution, a blue shift of the charge transfer band is observed when comparing compound 6 (352 nm) with compound 7 (305 nm), as well as comparing compound 8 (363 nm) with compound 9 (307 nm), as shown in FIG. 5. In addition, the transition energies of these charge transfer bands are found to be dependent on the nature of the electron-donating and accepting units. A red-shifted absorption band is observed from compound 6 (352 nm) to compound 8 (363 nm) which bear phenylbenzimidazole and oxadiazole units respectively as observed in FIG. 5. Significant red shift is also noticed when comparing the triphenylamine containing compound 6 (383 nm) to the carbazole-containing compound 7 (363 nm). This can be rationalized by the higher-lying HOMO level of triphenylamine than that of carbazole as shown in FIGS. 5 and 6. The lower-energy absorptions beyond 390 nm are attributed to IL .fwdarw.* transitions of the bzimb ligand, with substantial mixing of MLCT [d(Pt).fwdarw.*(bzimb)] and LLCT [(CCR).fwdarw.*(bzimb)] character.

Example 4

[0124] Photoluminescence Properties

[0125] In degassed dichloromethane solution, compounds 1-9 and 11-13 show a vibronic-structured emission band with emission maxima at ca. 511-530 nm, and progressional spacings of about 1300 cm.sup.1, corresponding to typical aromatic vibrational modes of the bzimb-based ligands as shown in FIGS. 7-9. The emission has been assigned to be originated from the .sup.3IL[.fwdarw.*(bzimb)]/MLCT[d(Pt).fwdarw.*(bzimb)] excited state, as supported by the insensitivity of the emission band towards the choice of the alkynes. The emission energy is found to be sensitive to the substitution on the 5-position of the bzimb ligands. A red shift of the emission band with emission maxima at 530 nm is observed for compounds 12 and 13 as shown in FIG. 7. The introduction of dendritic carbazole moiety at the 5-position of the bzimb ligand which is connected through the electron-donating nitrogen atom would raise the energy of the HOMO level to a larger extent than that of the LUMO level, similar to the UV-vis absorption studies. This would therefore lead to the red-shift in energy. FIG. 10 displays the photoluminescence spectra for compounds 10 and 14 in dichloromethane at 298 K. A dual-emissive behavior has been observed for compounds 10 and 14. Apart from the .sup.3IL emission similar to the other compounds, an additional higher-energy structureless emission at ca. 468 nm is found. This band could be assigned as the intramolecular charge transfer excited state (.sup.1ICT) of the triphenylamine-oxadiazole donor-acceptor pair on the alkynes.

[0126] FIG. 11 depicts the thin-film emission spectra of 20 wt % compounds 6-9 doped in mixed host consisting of TCTA:SPPO13 (1:1), whereas FIG. 12 shows the thin-film emission spectra of 5 wt % compounds 5, 11-13 doped in MCP. The emission spectra are almost identical to their corresponding emission spectra in solution without undesirable emission from the host materials, indicating the complete energy transfer from the host materials to the guest complexes.

TABLE-US-00001 TABLE 1 Photophysical data for compounds 1-14 Absorption .sub.max/nm Emission .sub.max/nm Compound Medium (T/K) (/dm.sup.3mol.sup.1cm.sup.1) (.sub.0/s) .sub.sol .sub.film 1 CH.sub.2Cl.sub.2 (298) 287 (48360), 297 517, 555, 600 (6.0) 0.34.sup.[a] 0.74.sup.[c] (65310), 313 (48360), 344 (22310), 386 (15910), 405 (16460) 2 CH.sub.2Cl.sub.2 (298) 287 (112995), 298 517, 555, 600 (5.8) 0.48.sup.[a] 0.54.sup.[c] (128500), 318 (60290), 349 (31580), 380 (10290), 407 (9130) 3 CH.sub.2Cl.sub.2 (298) 298 (49070), 308 525, 567, 616 (3.1) 0.55.sup.[a] 0.68.sup.[c] (40990), 322 (36960), 352 (18300), 393 (9270), 440 (10800) 4 CH.sub.2Cl.sub.2 (298) 298 (100060), 323 525, 567, 616 (3.3) 0.69.sup.[a] 0.79.sup.[c] (51880), 349 (27630), 392 (11750), 433 (11750) 5 CH.sub.2Cl.sub.2 (298) 290 (79780), 300 518, 556, 600 (5.7) 0.47.sup.[a] 0.83.sup.[c] (104160), 316 (75820), 346 (38490), 390 (22565), 414 (14650) 6 CH.sub.2Cl.sub.2 (298) 297 (121970), 318 511, 550, 595 (3.3) 0.49.sup.[a] 0.47.sup.[d] (134385), 342 (103920), 352 (84960), 412 (13650) 7 CH.sub.2Cl.sub.2 (298) 297 (167070), 305 511, 550, 595 (3.3) 0.59.sup.[a] 0.62.sup.[d] (147940), 342 (50900), 365 (31705), 412 (13650) 8 CH.sub.2Cl.sub.2 (298) 297 (133250), 316 511, 550, 595 (3.6) 0.64.sup.[a] 0.63.sup.[d] (131570), 343 (103320), 363 (85560), 412 (13650) 9 CH.sub.2Cl.sub.2 (298) 297 (187940), 307 511, 550, 595 (3.5) 0.59.sup.[a] 0.65.sup.[d] (162030), 342 (50900), 365 (31705), 412 (13650) 10 CH.sub.2Cl.sub.2 (298) 296 (153220), 310 468, 504, 549, 595 0.60.sup.[b] 0.42.sup.[c] (121910), 353 (73390), (<0.1, 3.8).sup.[e] 383 (86880), 433 (14550) 11 CH.sub.2Cl.sub.2 (298) 287 (208510), 298 520, 558, 602 (6.2) 0.54.sup.[a] 0.59.sup.[c] (245840), 317 (122330), 350 (69615), 384 (26520), 414 (13480) 12 CH.sub.2Cl.sub.2 (298) 297 (126770), 310 526, 565, 610 (5.8) 0.64.sup.[a] 0.76.sup.[c] (81420), 350 (36140), 373 (27650), 440 (7080) 13 CH.sub.2Cl.sub.2 (298) 297 (184820), 313 525, 568, 607 (6.5) 0.64.sup.[a] 0.65.sup.[c] (101290), 349 (51020), 373 (37550), 438 (10660) 14 CH.sub.2Cl.sub.2 (298) 297 (182900), 309 468, 515, 558, 610 0.56.sup.[b] 0.65.sup.[d] (132160), 338 (58750), (<0.1, 2.8).sup.[e] 384 (87420), 440 (17790) .sup.[a]The luminescence quantum yield, measured at room temperature using [Ru(bpy).sub.3]Cl.sub.2 in aqueous state as the reference (excitation wavelength = 436 nm, .sub.lum = 0.042) .sup.[b]The luminescence quantum yield, measured at room temperature using quinine sulphate in 1.0N H.sub.2SO.sub.4 as the reference (excitation wavelength = 366 nm, .sub.lum = 0.546) .sup.[c].sub.film of Pt(II) compounds doped into MCP excited at wavelength of 300 nm .sup.[d].sub.film of Pt(II) compounds doped into TCTA:SPPO13 (1:1) excited at wavelength of 300 nm .sup.[e]Biexponential decay

Example 5

[0127] An organic EL device according to an embodiment of the invention was constructed in the following manner:

[0128] a) A transparent anode ITO-coated borosilicate glass substrate (38 mm38 mm) with sheet resistance of 30 per square was ultrasonicated in the commercial detergent Decon 90, rinsed in deionized water having a resistivity of 18.2 mega-ohm for 15 minutes, and then dried in an oven at 120 degree C. for an hour. The substrate was next subjected to an UV-ozone treatment in a Jelight 42-220 UVO-Cleaner equipped with a mercury grid lamp for 15 minutes in order to increase the work function of the ITO-coated glass substrate for better hole injection into the organic layer;

[0129] b) A 70-nm thick PEDOT:PSS hole-transporting layer was spin-coated by using a Laurell WS-400Ez-6NPP-Lit2 single wafer spin processor at 7000 rpm from 30 seconds onto the ITO-coated glass substrate of step a and baked at 110 degree C. for 10 minutes in air;

[0130] c) A 60-nm thick light-emitting layer was spin-coated by using a Laurell WS-400Ez-6NPP-Lit2 single wafer spin processor at 6000 rpm from 25 seconds onto the PEDOT:PSS layer of step b and baked at 80 degree C. for 10 minutes in air, in which compound 6 was doped into light-emitting TCTA:SPPO13 (1:1) layer at different concentrations in the range from 5 to 50 wt %;

[0131] d) The substrate was put into a vacuum chamber, and the chamber was pumped down from 1 bar to 510.sup.6 mbar;

[0132] e) A 30-nm thick BmPyPhB electron-transporting layer was deposited by thermal evaporation onto the light-emitting layer of step c.

[0133] f) A 0.8-nm thick LiF layer and a 80 nm thick Al layer were deposited by thermal evaporation on BmPyPhB of step e to form an electron-injecting cathode.

[0134] All materials were prepared by thermal evaporation from tantalum boats by applying current through the tantalum boats. Deposition rates were monitored with a quartz oscillation crystal and a Sigma SQM-242 quartz crystal card and controlled at 0.1-0.2 nm s.sup.1 for both organic and metal layers. Current density-voltage-luminance characteristics of organic EL devices were measured with a programmable Keithley model 2420 power source and a Spectrascan PR 655 colorimeter under ambient air conditions.

Example 6

[0135] The same materials and processing procedures were employed as described in Example 5, except that compounds 7-9 were doped into TCTA:SPP013 as light-emitting layer.

[0136] FIG. 13 depicts the normalized EL spectra of the devices at a current density of 20 mA cm.sup.2. All the devices exhibit vibronic-structured emission, and the EL spectra for all the devices are exactly identical to their emission spectra in solution. Notably, the full-width-at-half-maxima of all the devices remain unchanged upon increasing the dopant concentration from 5 wt % to 20 wt %. In addition, both x and y chromaticity coordinates of all the devices are only varied by less than 0.02. This concentration-independent EL suggests the low tendency of the bipolar platinum(II) complexes to form aggregates through Pt . . . Pt and/or - stacking in the thin films, in excellent agreement with the photoluminescence studies.

[0137] FIG. 14 shows the EQEs of solution-processable OLEDs doped with compounds 6-9 and Table 2 summarizes the key device performance. As expected, devices with OXD electron-transporting groups are much better than those with PBI moieties with the same linkage mode. For instance, with the para-substituted electron-transporting group, the current efficiency and EQE are increased from 24.5 cd A.sup.1 and 7.1% for device made with 6 to 35.1 cd A.sup.1 and 9.8% for device doped with 8. The discrepancies on device efficiencies are believed to be due to a better electron-transporting property of OXD than PBI. More importantly, the device performances can be further boosted up by the introduction of meta-substitution. Devices with meta-substituted PBI moieties (i. E. 7) are much more superior to those with para-substituted counterpart (i. E. 6), in which both current efficiency and EQE are increased by 64% via meta-linkage. Similar EQE increment can be obtained for devices with OXD electron-transporting groups (i. E. 8 and 9). High current efficiency of 57.4 cd A.sup.1 and EQE of 16.0% can be realized for devices made with 9. Such high EQE value is one of the highest amongst solution-processable PHOLEDs based on platinum(II) complexes, as well as solution-processable PHOLEDs based on bipolar iridium(III) and gold(III) complexes.

Example 7

[0138] The same materials and processing procedures were employed as described in Example 5, except that compounds 12 and 13 were doped into TCTA:MCP (1:3) as light-emitting layer.

[0139] FIG. 15 shows the normalized EL spectra of devices doped with 6-9, 12 and 13 at a current density of 20 mA cm.sup.2. In good agreement with the emission studies, the EL spectra of devices made with compounds 12 and 13 have been slightly red shifted by 8 nm. Such red shift could be rationalized by the direct incorporation of the carbazole dendrimers at the 5-position of the bzimb ligand, leading to the destabilization of the HOMO energy level in 12 and 13.

TABLE-US-00002 TABLE 2 Key parameters of solution-processsable OLEDs based on compounds 6-9, 12 and 13 Dopant Max. Current Max. Power Concentration/ Efficiency/cd Efficiency/lm Complex wt % A.sup.1 W.sup.1 Max. EQE/% CIE (x, y).sup.[a] 6 15 24.5 8.1 7.1 0.38, 0.59 7 10 43.6 18.3 12.1 0.36, 0.61 8 10 35.1 14.7 9.8 0.37, 0.60 9 15 57.4 27.7 16.0 0.37, 0.60 12 15 19.2 12.5 5.3 0.37, 0.60 13 20 17.7 10.1 5.0 0.38, 0.60 .sup.[a]Data were collected at a current density of 20 mA cm.sup.2.